Longeveron Inc. (LGVN)
NASDAQ: LGVN · Real-Time Price · USD
1.170
+0.070 (6.36%)
Apr 7, 2026, 11:15 AM EDT - Market open
Longeveron Employees
Longeveron had 38 employees as of December 31, 2025. The number of employees increased by 12 or 46.15% compared to the previous year.
Employees
38
Change (1Y)
12
Growth (1Y)
46.15%
Revenue / Employee
$31,553
Profits / Employee
-$597,474
Market Cap
34.26M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 38 | 12 | 46.15% | 38 | 0 |
| Dec 31, 2024 | 26 | 2 | 8.33% | 26 | 0 |
| Dec 31, 2023 | 24 | 3 | 14.29% | 23 | 1 |
| Dec 31, 2022 | 21 | 1 | 5.00% | 19 | 2 |
| Dec 31, 2021 | 20 | 8 | 66.67% | 18 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Evaxion | 46 |
| Senti Biosciences | 34 |
| Palatin Technologies | 29 |
| Actinium Pharmaceuticals | 25 |
| INmune Bio | 21 |
| ABVC BioPharma | 19 |
| BriaCell Therapeutics | 16 |
LGVN News
- 20 days ago - Longeveron Announces 2025 Full Year Financial Results and Provides Business Update - GlobeNewsWire
- 20 days ago - Longeveron Braces For Q4 Results Following Recent Funding Boost - Benzinga
- 26 days ago - Longeveron Announces Closing of Private Placement of up to $30 Million - GlobeNewsWire
- 27 days ago - Longeveron (LGVN) Shares Surge On $30 Million Private Placement Deal - Benzinga
- 5 weeks ago - Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell - GlobeNewsWire
- 7 weeks ago - Longeveron® Appoints Stephen H. Willard as Chief Executive Officer - GlobeNewsWire
- 2 months ago - Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program - GlobeNewsWire
- 2 months ago - Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs) - GlobeNewsWire